Translating Causation To Treatment - Reviewing The Microbiome's Role In Drug Development
8.30
Patient Engagement Facilitates Drug Development: Starting & Ending with the Patient in Mind
Bernat Olle
CEO
Vedanta Biosciences
Colleen Cutcliffe
CEO
Whole Biome
9.30
Healthy Infants Harbour Intestinal Bacteria That Protect Against Food Allergy
Cathryn Nagler
Bunning Food Allergy
Professor
University of Chicago
10.00
Microbiome Tools & Trends for the Pharmaceutical Industry
Julia Cope
Director of Scientific
Operations
Diversigen
10.30
Shotgun Sequencing & Strain-Level Analysis: Study Design for Pre-Clinical & Clinical Development
Nur Hasan
Chief Scientific Officer
CosmosID
11.00
Morning Refreshments and Speed Networking
STREAM A:
12.00 | A Preclinical Assessment of a Rationally Designed LBP |
Esi Lamouse-Smith, |
12.30 |
Translating Probiotic Research into LBP Drug Programs
|
Nigel Titford, Chief Executive Officer, Biogaia Pharma |
STREAM B:
STREAM C: